Julien Smith-Roberge
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Research Interests
Julien Smith-Roberge has a total of 5 co-authors. Here are the top co-authors by number of shared publications:
- Abdullah Hamadeh
School of Pharmacy University of Waterloo Kitchener Ontario Canada
2 shared publications - Farinaz Forouzannia
Affiliation School of Pharmacy, University of Waterloo, Kitchener, ON, Canada
2 shared publications - Nashira Popovic
Centre for Outcomes Research and Evaluation Research Institute of the McGill University Health Centre (MUHC) Montréal Québec Canada
2 shared publications - William W. L. Wong
School of Pharmacy, University of Waterloo, Kitchener, Ontario, Canada
2 shared publications - Zeny Feng
Department of Mathematics and Statistics, University of Guelph, Guelph, Ontario, Canada
2 shared publications
Latest Publications
- Open Access
- 20 August 2025
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 11, e66309
Estimating Chronic Hepatitis B Prevalence and Undiagnosed Proportion in Canada, 2007-2021: Mathematical Framework Development
Background: Chronic hepatitis B (CHB) remains a significant health burden for at least a hundred thousand Canadians. The government of Canada has endorsed the global strategy to eliminate hepatitis as a public health threat by 2030, but effectively targeting public health interventions is complicated by the silent nature of the disease, which can remain asymptomatic for decades. Objective: This study develops a framework to estimate the prevalence of CHB and the proportion of the infected population that remains undiagnosed. We apply the proposed method to national data from Canada, from 2007 to 2021. Methods: We infer the prevalence and undiagnosed proportion of CHB by fitting a mathematical state-transition model, based on the natural history of CHB, to observed CHB-related events. Data for the calibration were obtained from the Public Health Agency of Canada and Statistics Canada. Results: We estimate the national prevalence of CHB in Canada in 2021 to be 0.483% (95% CI 0.443%-0.535%). The corresponding percentage of undiagnosed cases was estimated to be 54.3% (95% CI 50.9%-58.9%). Conclusions: The estimates of CHB prevalence obtained via our method are in line with previous estimates obtained from national seroprevalence studies. More specialized estimates, stratified by province or age cohort, may be achievable with detailed health administrative data.
- 20 August 2025
- Published by JMIR Publications Inc. in JMIR Public Health and Surveillance
- Vol. 11, e66309
Open AccessEstimating Chronic Hepatitis B Prevalence and Undiagnosed Proportion in Canada, 2007-2021: Mathematical Framework Development
Background: Chronic hepatitis B (CHB) remains a significant health burden for at least a hundred thousand Canadians. The government of Canada has endorsed the global strategy to eliminate hepatitis as a public health threat by 2030, but effectively targeting public health interventions is complicated by the silent nature of the disease, which can remain asymptomatic for decades. Objective: This study develops a framework to estimate the prevalence of CHB and the proportion of the infected population that remains undiagnosed. We apply the proposed method to national data from Canada, from 2007 to 2021. Methods: We infer the prevalence and undiagnosed proportion of CHB by fitting a mathematical state-transition model, based on the natural history of CHB, to observed CHB-related events. Data for the calibration were obtained from the Public Health Agency of Canada and Statistics Canada. Results: We estimate the national prevalence of CHB in Canada in 2021 to be 0.483% (95% CI 0.443%-0.535%). The corresponding percentage of undiagnosed cases was estimated to be 54.3% (95% CI 50.9%-58.9%). Conclusions: The estimates of CHB prevalence obtained via our method are in line with previous estimates obtained from national seroprevalence studies. More specialized estimates, stratified by province or age cohort, may be achievable with detailed health administrative data.
- Open Access
- 16 September 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Estimating Chronic Hepatitis B Prevalence and Undiagnosed Proportion in Canada, 2007-2021: Mathematical Framework Development (Preprint)
BACKGROUND Chronic hepatitis B (CHB) remains a significant health burden for at least a hundred thousand Canadians. The government of Canada has endorsed the Global Strategy to eliminate hepatitis as a public health threat by 2030, but effectively targeting public health interventions is complicated by the silent nature of the disease, which can remain asymptomatic for decades. OBJECTIVE This study develops a framework to estimate the prevalence of chronic hepatitis B and the proportion of the infected population that remains undiagnosed. We apply the proposed method to national data from Canada, from 2007 to 2021. METHODS We infer the prevalence and undiagnosed proportion of CHB by fitting a mathematical state-transition model, based on the natural history of chronic hepatitis B, to observed CHB-related events. Data for the calibration were obtained from the Public Health Agency of Canada and Statistics Canada. RESULTS We estimate the national prevalence of CHB in Canada in 2021 to be 0.483% (95% CI: 0.443% - 0.535%). The corresponding percentage of undiagnosed cases was estimated to be 54.3% (95% CI: 50.9% - 58.9%). CONCLUSIONS The estimates of CHB prevalence obtained via our method are in line with previous estimates obtained from national seroprevalence studies. More specialized estimates, stratified by province or age cohort, may be achievable with detailed health administrative data. CLINICALTRIAL
- 16 September 2024
- Published by JMIR Publications Inc. in JMIR Preprints
Open AccessEstimating Chronic Hepatitis B Prevalence and Undiagnosed Proportion in Canada, 2007-2021: Mathematical Framework Development (Preprint)
BACKGROUND Chronic hepatitis B (CHB) remains a significant health burden for at least a hundred thousand Canadians. The government of Canada has endorsed the Global Strategy to eliminate hepatitis as a public health threat by 2030, but effectively targeting public health interventions is complicated by the silent nature of the disease, which can remain asymptomatic for decades. OBJECTIVE This study develops a framework to estimate the prevalence of chronic hepatitis B and the proportion of the infected population that remains undiagnosed. We apply the proposed method to national data from Canada, from 2007 to 2021. METHODS We infer the prevalence and undiagnosed proportion of CHB by fitting a mathematical state-transition model, based on the natural history of chronic hepatitis B, to observed CHB-related events. Data for the calibration were obtained from the Public Health Agency of Canada and Statistics Canada. RESULTS We estimate the national prevalence of CHB in Canada in 2021 to be 0.483% (95% CI: 0.443% - 0.535%). The corresponding percentage of undiagnosed cases was estimated to be 54.3% (95% CI: 50.9% - 58.9%). CONCLUSIONS The estimates of CHB prevalence obtained via our method are in line with previous estimates obtained from national seroprevalence studies. More specialized estimates, stratified by province or age cohort, may be achievable with detailed health administrative data. CLINICALTRIAL